About
Prior to founding his consulting practice, Dr. Cox was Chief Medical Officer for Editas Medicine, in Cambridge, where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases, resulting in the first IND approval for in vivo delivery of CRISPR/Cas9 gene editing. Dr. Cox also had a long stint at Sanofi Genzyme, also in Cambridge, culminating as Vice President, Rare Disease Clinical Development, where he oversaw multiple global rare disease clinical development programs, including Cerdelga®; olipudase alfa; Hectoral®; Cerezyme®, and Aldurazyme®, as well as Elaprase® in Asia, among others. Before then, Dr. Cox held several senior medical R&D positions at Genzyme and was the company’s first clinical geneticist recruited to oversee human clinical development programs for rare genetic diseases. Dr. Cox is a board-certified clinical geneticist and pediatrician who trained at Boston Children’s Hospital, where he remains on staff and continues to see p
Investment Focus
- Location
- Novato, US
Contact Information
Find more investors like Gerald
Search Investors